Annexon Biosciences
Annexon Biosciences is a clinical-stage biopharmaceutical company pioneering the development of a new class of medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. The company’s pipeline is based on its platform technologies addressing a broad spectrum of well-researched classical complement-mediated autoimmune and neurodegenerative diseases triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is advancing a portfolio of innovative product candidates designed to block the activity of C1q and the entire classical complement pathway. Annexon is deploying a disciplined, unbiased biomarker-driven strategy designed to improve the probability of technical success of its portfolio and striving to deliver precision medicine to patients with classical complement driven diseases in the body, brain and eye.
OPEN POSITIONS
We are looking for talented individuals to join our experienced, collaborative and driven team. Those who are passionate about making a difference in the lives of patients and their families and who bring that drive and dedication to the workplace are encouraged to apply.